These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1916927)

  • 1. Immunological aspects of clinical renal transplantation.
    Propper DJ; Catto GR
    Immunol Lett; 1991 Jul; 29(1-2):65-7. PubMed ID: 1916927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local immunosuppression of canine renal allografts with 15-deoxyspergualin.
    Hughes SE; Xiao S; Perera S; Fluno C; Hasselbarth J; Jayasankar V; Singh J; Del Rosario A; Freed BM; Singh TP; Lempert N; Conti DJ; Gruber SA
    Transplant Proc; 1996 Aug; 28(4):2054-5. PubMed ID: 8769153
    [No Abstract]   [Full Text] [Related]  

  • 3. [Renal transplantation - new developments].
    Eisenberger U
    Ther Umsch; 2011 Dec; 68(12):687-92. PubMed ID: 22139983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic rejection of renal allografts with four immunosuppressive regimens.
    Isoniemi H; Ahonen J; Krogerus L; Eklund B; Höckerstedt K; Salmela K; Häyry P
    Transplant Proc; 1992 Dec; 24(6):2716-7. PubMed ID: 1465912
    [No Abstract]   [Full Text] [Related]  

  • 5. Mofetil mycophenolate in renal transplantation.
    Pretagostini R; Rossi M; Berloco P; Colonnello M; Bruzzone P; Peritore D; Lonardo MT; Cortesini R
    Transplant Proc; 2001; 33(1-2):1082-3. PubMed ID: 11267200
    [No Abstract]   [Full Text] [Related]  

  • 6. A retrospective analysis of a sirolimus/prograf regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts.
    Youseff N; Small S
    Transplant Proc; 2002 Aug; 34(5):1653-5. PubMed ID: 12176522
    [No Abstract]   [Full Text] [Related]  

  • 7. Excellent outcome with a calcium channel blocker-supplemented immunosuppressive regimen in cadaveric renal transplantation. A potential strategy to avoid antibody induction protocols.
    Suthanthiran M; Haschemeyer RH; Riggio RR; Adubor C; Friedman GS; Cheigh JS; Wang JC; Fotino M; Stubenbord WT; Saal SD
    Transplantation; 1993 May; 55(5):1008-13. PubMed ID: 8497873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical application of immunosuppressive agents in renal transplantation.
    First MR
    Surg Clin North Am; 1998 Feb; 78(1):61-76. PubMed ID: 9531936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic renal allograft damage: existing challenges.
    Arias M; Serón D; Moreso F; Bestard O; Praga M
    Transplantation; 2011 May; 91(9 Suppl):S4-25. PubMed ID: 21519213
    [No Abstract]   [Full Text] [Related]  

  • 10. Application of cyclosporine in renal transplantation: experience at the University of Padua.
    Furian L; Baldan N; Rigotti P
    Transplant Proc; 2004 Mar; 36(2 Suppl):148S-151S. PubMed ID: 15041326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotoxicity-free, mycophenolate mofetil-based induction/maintenance immunosuppression in elderly recipients of renal allografts from elderly cadaveric donors.
    Theodorakis J; Schneeberger H; Illner WD; Stangl M; Zanker B; Land W
    Transplant Proc; 2000 Feb; 32(1A Suppl):9S-11S. PubMed ID: 10686311
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence on the long-term outcome of renal allografts by fosfomycin.
    Hoyer J; Winterhoff R; Fricke L; Sack K
    Transplant Proc; 1997 Nov; 29(7):2948-50. PubMed ID: 9365624
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunosuppressive regimens and their effects on renal allograft outcome.
    Katznelson S; Cecka JM
    Clin Transpl; 1996; ():361-71. PubMed ID: 9286582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longterm renal allograft survival after sequential liver-kidney transplantation from a single living donor.
    Kitajima K; Ogawa Y; Miki K; Kai K; Sannomiya A; Iwadoh K; Murakami T; Koyama I; Nakajima I; Fuchinoue S
    Liver Transpl; 2017 Mar; 23(3):315-323. PubMed ID: 27862900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withdrawal of steroids from a cyclosporine-based regimen: pro.
    Ponticelli C
    Transplant Proc; 1998 Aug; 30(5):1782-4. PubMed ID: 9723281
    [No Abstract]   [Full Text] [Related]  

  • 16. OKT3 in renal allografts: survival and complications.
    D'Souza RJ; Kwan JT; Chang R; Bending MR
    Clin Nephrol; 1999 Apr; 51(4):257-8. PubMed ID: 10230561
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of simulect can reduce the incidence of acute rejection and demonstrates with superior 3-year patient and graft survival rates in renal transplantation.
    Chu SH; Chiang YJ; Huang CC; Lee PH; Hu RH; Lai MK; Chueh SC; Tsai MK
    Transplant Proc; 2004 Sep; 36(7):2108-9. PubMed ID: 15518763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.
    Gralla J; Wiseman AC
    Transplantation; 2009 Jun; 87(11):1712-9. PubMed ID: 19502965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of single versus double CsA dosing in kidney transplantation.
    Tarantino A; Montagnino G; Cesana B; Aroldi A; Campise M; Passerini P; Ponticelli C
    Transplant Proc; 2001; 33(7-8):3409-10. PubMed ID: 11750459
    [No Abstract]   [Full Text] [Related]  

  • 20. Renal transplantation in a new immunosuppressive era.
    Ciancio G; Roth D; Burke G; Nery J; Scantlebury V; Shapiro R; Esquenazi V; Olson L; Gharagozloo H; Miller J
    Transplant Proc; 1995 Feb; 27(1):812-3. PubMed ID: 7879195
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.